Policy Options for Formulary Development in Middle-income Countries

Hernandez-Villafuerte, K., Garau, M., Towse, A., Garrison, L. and Grewal, S.

Consulting Report
January 2017

Sign Up for OHE Updates

Why not sign up for our email updates? Around once or twice a week we will send you a round-up of the latest news, events and publications from OHE.

I'm already signed up    No thanks

PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion.

This report presents a framework for developing medicines formularies which combines macro-level decision making factors (focusing on the health system organisation and its priority setting), and micro-level factors (looking at intervention-specific effects) to determine the overall value of medicines.

In a susbequent publication (click here) we apply this framework to analyse the Mexican decision making process for the inclusion of a new health treatment in the positive list. We propose a series of recommendations that could improve the efficiency of the Mexican decision making process.